Principal Scientist (CRISPR Screening) - Definigen

Principal Scientist (CRISPR Screening)

Salary: Competitive plus benefits including pension and share options

Location: Babraham Research Campus, Cambridge, UK

Type: Permanent, Full time Start: Immediate

Closing date: 7th June 2021

We are seeking a highly experienced and ambitious individual to establish a CRISPR Screening unit at DefiniGEN. This is a great opportunity for someone with hands-on experience in CRISPR screening to form their own team and service offering within a growing biotechnology company. 

You will be responsible for the establishment of novel CRISPR screening assays in our cell-based model systems. The successful candidate will be required to work in a dynamic environment with multiple teams working in parallel. The main role will be to develop and conduct innovative screening assays for iPSC-derived cells using CRISPR technology, high-throughput screening, and various automation techniques.

This role will be laboratory based and the successful candidate will be able to work to tight deadlines and have some experience in line management.

Key Roles and Responsibilities 

  • Establishment of CRISPR screening capability at DefiniGEN
  • Plan and perform custom CRISPR screening experiments in iPSCs and their derivatives.
  • Work in cross-functional teams and conduct complex gene editing core/custom projects.
  • Develop and evaluate automation-compatible high-throughput biochemical and cell-based assays for compound and target validation.
  • Develop new innovative products and gene editing services that can be launched to the market.
  • Analyse and interpret high-volume screening data, troubleshoot, discuss results, and identify next steps.
  • Report on milestone delivery for internal development project and provide status updates to the organisation.
  • Create standard operating procedures and training documentation to aid the implementation of changes.
  • Act as the company gene editing expert for client-specific and internal project enquiries.
  • Provide technical advice, guidance and mentoring to other team members.
  • Represent the business in client meetings and at scientific conferences.


  • An advanced degree (M.Sc or Ph.D.) in biological science or related field, plus 2+ years of experience in CRISPR screening (E)
  • Proven experience in planning and conducting complex cell-based screening assays (CRISPR, RNAi or compound screening), ideally in iPSC (E)
  • An expert in functional genomic screening (arrayed or pooled, CRISPR KO, CRISPRi or CRISPRa) (E)
  • Extensive experience of mammalian cell culture, ideally in maintaining and differentiating iPSC lines (D)
  • Experience with advanced molecular biology including in silico vector design (E)
  • Familiarity with the development/implementation of automation techniques (D)
  • Ability to handle large data sets, including data QC, analysis, interpretation, etc (E)
  • A quality mindset, with enthusiasm and commitment to achieve aims within tight deadlines and improve processes where possible (E)
  • Attention to detail and ability to run multiple projects at any given time (E)
  • Ability to work in cross-functional groups to transfer technology into other groups and support commercialisation (E)

This is an excellent opportunity for someone interested in pursuing a leadership career in a dynamic environment. To be considered for this opportunity you will possess up-to-date, hands-on experience in cell line engineering, CRISPR Screening and complex assays development, preferably in the life science or stem cell sectors. In return you will be offered an excellent salary and benefits package. Applicants should apply by sending their cover letter and CV to:

About us:                                                                            
Founded in 2013, DefiniGEN is a fast-growing provider of induced pluripotent stem cell (iPSC)-derived human cell disease models to support preclinical research. This cutting-edge platform can generate disease model human cells to support drug discovery, especially in orphan (rare) indications where no preclinical research models exist, and for metabolic disease research such as diabetes and NAFLD. The company uses CRISPR genome editing to manipulate the genome of the iPSC, then differentiates the stem cell into human-like diseased cells for screening and preclinical development.

Share this page